Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion

What happened

Eli Lilly entered a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion. The transaction includes an upfront cash payment along with additional milestone payments tied to clinical and regulatory achievements. Ajax's primary asset is AJ1-11095, an investigational once-daily oral therapy designed as a Type II JAK2 inhibitor. The drug is currently in Phase 1 clinical trials targeting myelofibrosis, a rare blood cancer that causes bone marrow scarring. All currently approved JAK2 inhibitors bind to the Type I conformation of the JAK2 enzyme, and many patients eventually stop responding to these therapies. AJ1-11095 was designed to bind to a different, inactive conformation of the enzyme, potentially addressing resistance mechanisms that limit the effectiveness of existing treatments. Lilly was a founding strategic investor in Ajax and participated in the company's $95 million Series C funding round in 2024. Proof-of-concept clinical data from the ongoing Phase 1 trial are expected later in 2026, and Lilly plans to select a dose for further development this year.

Why it matters

The acquisition strengthens Lilly's oncology pipeline, particularly in hematology, where the company aims to become a meaningful player. Myelofibrosis patients often discontinue existing JAK2 inhibitors due to loss of response or safety concerns, creating demand for therapies that work differently. AJ1-11095's mechanism—targeting an inactive form of the JAK2 enzyme—could potentially offer deeper and more durable responses than current options, or serve as a new treatment for patients who develop resistance. Lilly's prior involvement as a founding investor suggests familiarity with the underlying science and confidence in the asset's potential. The deal represents Lilly's second oncology acquisition this month, following a $7 billion agreement to acquire Kelonia Therapeutics, and reflects the company's strategy of reinvesting proceeds from its diabetes and obesity portfolio into cancer and related therapeutic areas.

Bigger picture

This transaction extends a dealmaking surge for Lilly, which has acquired five companies since the start of 2025, with four of those deals occurring since late March. The company has adopted a "land grab" strategy of acquiring differentiated, mechanistically compelling assets early in development, before data readouts that can drive up valuations. Lilly is now the world's most valuable pharmaceutical company, driven by fast-growing sales of its obesity and diabetes drugs. The Ajax acquisition fits into a broader industry trend, with 2025 on track to become one of the most active years for pharmaceutical M&A. For the JAK inhibitor market, the deal highlights ongoing efforts to address limitations of existing therapies, which have faced safety concerns and loss of efficacy over time in conditions like myelofibrosis, polycythemia vera, and rheumatoid arthritis.

What to watch

Investors should monitor the presentation of proof-of-concept clinical data from the ongoing Phase 1 trial later in 2025, which will provide the first substantive evidence of whether AJ1-11095 delivers on its mechanism-based promise. Lilly's dose selection for further development, expected this year, will also signal the company's confidence in advancing the asset into registrational studies. Broader trends in Lilly's oncology portfolio, including progress from the Kelonia acquisition and other recent deals, will shape perceptions of the company's strategic repositioning in cancer treatments. Additionally, any updates on the safety and efficacy profile of AJ1-11095 relative to existing JAK2 inhibitors will be critical for assessing commercial potential.

This article was generated by Quantli AI using publicly available news sources.